Bilbao, Spain
Bilbao, Spain

Time filter

Source Type

News Article | April 28, 2017
Site: marketersmedia.com

The acclaimed Cornita Mental Health & Medical Services has announced the launch of a new website detailing its professional, personalized and accredited counselling and psychotherapy services for patients of all ages across Reston, Virginia. More information is available at http://cornitamentalhealth-medicalservices.com. The Cornita Mental Health & Medical Services is a renowned and accredited medical practice based in Reston, Virginia, committed to providing children, adolescents, adults or geriatric patients with the professional, effective and personalized mental health and psychiatric care they need to take back control of their lives and achieve their highest potentials. The renowned mental health practice has announced the launch of a new website detailing its leading range of patient centered mental health and medical services, from psychiatric assessments and evaluations or medication management to the best counselling and psychotherapy in the area, available out of its welcoming, comfortable clinic in 1860 Town Center Drive, Suite 340, Reston, VA. The new website also provides extensive information on the its lead practitioner, Dr. Cordelia Nieketien-Tawari, a licensed and board certified family psychiatrist with over 14 years of experience helping patients with various forms of mental health issues such as anxiety disorders, depression, hyperactivity, attention deficit disorder (ADD), post-traumatic stress, bipolar disorder or psychosis, schizophrenia, and more. Appointments and free consultations with Dr. Cordelia Nieketien-Tawari or Cornita Mental Health & Medical Services and more information on its practice policies or patient centered mental health care philosophy are available at 571 230 9295 or through the newly launched website at the link provided above along with multiple patient testimonials and valuable ADD, eating or bipolar disorders and depression, substance abuse or PTSD education resources. The Cornita Mental Health & Medical Services team explains that “we have built our practice based on two fundamentals, namely, private personalized care; and respectful, healthy and caring relationships with all our patients. Our practitioners have extensive experience and expertise in offering people of all ages (pediatric, adolescent, adult and geriatric patients) with the professional, effective and personalized mental health care and medical services they need to take back control over their lives and achieve their highest potentials.” For more information, please visit http://cornitamentalhealth-medicalservices.com


News Article | April 17, 2017
Site: www.PR.com

The New Wake Up Beautiful Spa is Now Open Wake Up Beautiful, a medical beauty spa located in Laguna Niguel, CA, has undergone several months of construction and finally opened its new doors on April 3rd, 2017. The medical spa, which has been in business since 2001, now includes a fully functional Brow Bar for Microblading and Permanent Makeup treatments, as well as several private rooms for Eyelash Extensions, Body Sculpting, YAG and IPL Facials, Botox, Dermal Fillers and the NuLift Facelift with no downtime. Laguna Niguel, CA, April 15, 2017 --( Microblading, Permanent Makeup, and Eyelash Extensions have become some of the most sought after beauty procedures, and Wake Up Beautiful’s new facility is equipped to offer all three. Microblading is the newest craze in the Permanent Makeup field, as it mimics the appearance of hair in the brow line, providing fuller brows! Wake Up Beautiful also specializes in permanent eyeliner, as well as lip liner and color. In addition to these services, Wake Up Beautiful offers Body Sculpting, Hi-Tech Facials, and Medical Services such as Botox, Fillers, Intense Pulsed Light (IPL) facials, and Chemical Peels. Their body sculpting treatment is used to remove cellulite dimples and create smooth skin, while the Hi-Tech Facials utilizes YAG and IPL lasers to brighten and tighten skin. According to Wake Up Beautiful, all treatments are customizable to fit the client’s needs. Most recently, Wake Up Beautiful has added a service called NovaThreads, which is a non-surgical face lift procedure. NovaThreads are needles that have been pre-loaded with a Polydioxanone (PDA) thread, which stays in the subdermal level of the skin, leaving results for 12 to 15 months. Wake Up Beautiful is the first medical beauty spa in the Laguna Niguel area to offer the NovaThreads treatment. On Saturday, April 29th, 2017, Wake Up Beautiful will be hosting a Grand Opening Party from 12pm to 5pm. The event will include champagne, hors d’oeuvres, and discounted specials all day. Customers who join Wake Up Beautiful’s once or twice a month Hi-Tech Facial membership during the Grand Opening will receive add-on treatments for $25 per area. Additionally, if a customer books a Permanent Makeup or Microblading treatment, he or she will receive the second treatment for 35% off. Finally, medical treatment discounts are as follows: Botox will cost $10 per unit (25 unit minimum), Fillers are all buy one syringe, get the second one 35% off, and Viva RF treatments are discounted by $100. Attendance at the Grand Opening Party is required to unlock these savings. Laguna Niguel, CA, April 15, 2017 --( PR.com )-- Wake Up Beautiful , a medical beauty spa located in Laguna Niguel, CA, has undergone several months of construction and finally opened its new doors on April 3rd, 2017. The medical spa, which has been in business since 2001, now includes a fully functional Brow Bar for Microblading and Permanent Makeup treatments, as well as several private rooms for the other services offered.Microblading, Permanent Makeup, and Eyelash Extensions have become some of the most sought after beauty procedures, and Wake Up Beautiful’s new facility is equipped to offer all three. Microblading is the newest craze in the Permanent Makeup field, as it mimics the appearance of hair in the brow line, providing fuller brows! Wake Up Beautiful also specializes in permanent eyeliner, as well as lip liner and color.In addition to these services, Wake Up Beautiful offers Body Sculpting, Hi-Tech Facials, and Medical Services such as Botox, Fillers, Intense Pulsed Light (IPL) facials, and Chemical Peels. Their body sculpting treatment is used to remove cellulite dimples and create smooth skin, while the Hi-Tech Facials utilizes YAG and IPL lasers to brighten and tighten skin. According to Wake Up Beautiful, all treatments are customizable to fit the client’s needs.Most recently, Wake Up Beautiful has added a service called NovaThreads, which is a non-surgical face lift procedure. NovaThreads are needles that have been pre-loaded with a Polydioxanone (PDA) thread, which stays in the subdermal level of the skin, leaving results for 12 to 15 months. Wake Up Beautiful is the first medical beauty spa in the Laguna Niguel area to offer the NovaThreads treatment.On Saturday, April 29th, 2017, Wake Up Beautiful will be hosting a Grand Opening Party from 12pm to 5pm. The event will include champagne, hors d’oeuvres, and discounted specials all day. Customers who join Wake Up Beautiful’s once or twice a month Hi-Tech Facial membership during the Grand Opening will receive add-on treatments for $25 per area. Additionally, if a customer books a Permanent Makeup or Microblading treatment, he or she will receive the second treatment for 35% off. Finally, medical treatment discounts are as follows: Botox will cost $10 per unit (25 unit minimum), Fillers are all buy one syringe, get the second one 35% off, and Viva RF treatments are discounted by $100. Attendance at the Grand Opening Party is required to unlock these savings.


News Article | April 27, 2017
Site: www.marketwired.com

NEW YORK, NY--(Marketwired - Apr 27, 2017) - Rising India Inc. ( : RSII) is pleased to announce that Rising Biosciences, Inc., The Company's recently finalized merger entity, has officially launched its corporate website, www.Risingbiosciences.com detailing its mission statement, corporate objectives and newly appointed research executives. Rising Biosciences, Inc. is a research & development company focusing on oral and topical cannabis and non-cannabis based pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry. Operations will be helmed by a team of chemists, physicians, pharmacists and medical marijuana industry veterans for the development of products in a clinical lab environment with a focus on creating product that can be metabolized by the body more efficiently, and with delivery methods more acceptable than smoking, tinctures and oils available on the market today. In addition to C-Level execs including previously announced execs CEO Robert Weber and Jim DiPrima, who will serve as CFO, the Rising Biosciences has also secured Arthur Hall as Chief Operating Officer. Hall, a seasoned executive in the medical marijuana industry, has extensive experience in laboratory environments in the states of Washington and Oregon, as well as a hands-on background in processing and production, particularly in development of new safe extraction methods, which have become industry standards today. Rising Biosciences has assembled an impressive team of executives including its Chief Medical Officer, Gary C. Bernard, M.D. who also serves as President & CEO of Pointe Medical Services, Inc., Pointe Med Pharmacy and Live Well MD. Douglas Bowes will serve as Director of Brand Development for Rising Biosciences. Bowes is a successful entrepreneur with over 35 years and the principal owner of a state of the art sterile and non-sterile compounding pharmacy. Richard Vallette will serve as Director of Pharmacology for the company. He is a certified Pharmacy Regulatory Specialist with certifications in Specialty Pharmaceutical Compounding Techniques and He currently owns and operates a consulting business that provides regulatory and compliance strategies outlining the proper handling of pharmaceuticals to professionals in various medical fields. CEO Weber is thrilled with the recent appointments, "We are pleased to have assembled our core team of execs and researchers and anticipate explosive growth in the sector given the current industry climate and prospects therein. The business is now prepared to move forward with products we have been working on the first being a non-opioid topical pain cream and the second being a peptide based serum for post melanoma scar reduction although not cannabis based products they will be marketable worldwide." We also are pleased to announce the Ohio location has begun renovation and we anticipate completion this quarter. Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.


News Article | April 27, 2017
Site: globenewswire.com

* Constant currency revenue, core revenue, non-GAAP EPS, non-GAAP gross margin and non-GAAP net income (referenced below) are non-GAAP financial measures. A reconciliation of these and other non-GAAP financial measures used in this release to their most directly comparable GAAP financial measure is included under the heading “Non-GAAP Financial Measures” below. SOUTH JORDAN, Utah, April 27, 2017 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy, today announced sales of $171.1 million for the quarter ended March 31, 2017, an increase of 23.9% over sales of $138.1 million for the quarter ended March 31, 2016.  On a constant currency basis, sales for the first quarter of 2017 would have been up 24.8% over sales for the comparable quarter of 2016. Merit’s GAAP net income for the first quarter of 2017 was $14.8 million, or $0.32 per share, compared to $4.4 million, or $0.10 per share, for the first quarter of 2016. GAAP net income for the first quarter of 2017 included a bargain purchase gain of approximately $12.2 million, or $0.27 per share pre-tax, which Merit recognized as a result of its acquisition of the critical care division of Argon Medical Devices, Inc., and approximately $(4.8) million, or $(0.11) per share pre-tax, of legal expenses Merit incurred in responding to the pending subpoena from the Department of Justice.  Merit’s non-GAAP net income* for the quarter ended March 31, 2017 was $12.7 million, or $0.28 per share, compared to $8.3 million, or $0.19 per share, for the quarter ended March 31, 2016. Given the circumstances of the Argon acquisition, which closed during the first quarter of 2017, and the complexity of the transaction, the entire purchase price allocation for the transaction (as well as the gain on bargain purchase) is considered provisional at this time and is subject to adjustment to reflect new information obtained about factors and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date, while the measurement period remains open. Merit’s sales by category for the three months ended March 31, 2017, compared to the corresponding period in 2016, were as follows: “Our management team is pleased with our performance during the first quarter, especially with the activities involved in the integration of the acquisitions of DFINE, the critical care division of Argon and the assets of Catheter Connections,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer.  “We delivered strong revenue growth across all sales divisions in the first quarter.” “We continue to focus on our promised deliverables, revenue growth, gross margin expansion, our R&D pipeline, and discipline in controlling our SG&A expenses,” Lampropoulos said. “We plan to deliver a two-year extension of our three-year plan following the second quarter of 2017,” Lampropoulos added.  “We reaffirm our revenue guidance of $713-$723 million and non-GAAP earnings of $1.15-$1.20 per share for the year ending December 31, 2017, without reduction due to our recent public stock offering.  Our guidance on GAAP EPS for the year ending December 31, 2017 is updated from $0.54-$0.60 to $0.80-$0.86 to reflect the bargain purchase gain recognized from the Argon acquisition.” 2017 GUIDANCE Based upon information currently available to Merit's management, Merit estimates that for the year ending December 31, 2017, absent material acquisitions or non-recurring transactions, Merit's revenues will be in the range of $713-$723 million, an increase of approximately 18-20%, compared to revenues of $603.8 million for the year ended December 31, 2016.  Also, based on information currently available to Merit's management, Merit estimates that, absent material acquisitions or non-recurring transactions, Merit's GAAP earnings per share for 2017 will be in the range of $0.80-$0.86 and non-GAAP* earnings per share for 2017 will be in the range of $1.15-$1.20. Merit’s financial guidance for the year ending December 31, 2017 is subject to risks and uncertainties, including, but not limited to, potential accounting adjustments attributable to Merit’s ongoing valuation of intangibles and other financial assets acquired from Argon Medical Devices, Inc. and Catheter Connections, Inc., as well as risks and uncertainties identified in Merit’s public filings. CONFERENCE CALL Merit will hold its investor conference call (conference ID 1848749) today, Thursday, April 27, 2017, at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific).  The domestic telephone number is (844) 578-9672, and the international number is (508) 637-5656.  A live webcast will also be available for the conference call at www.merit.com/investors. Non-GAAP Financial Measures Although Merit’s financial statements are prepared in accordance with accounting principles which are generally accepted in the United States of America (“GAAP”), Merit’s management believes that certain non-GAAP financial measures referred to in this release provide investors with useful information regarding the underlying business trends and performance of Merit’s ongoing operations and can be useful for period-over-period comparisons of such operations.  Non-GAAP financial measures used in this release include: Merit’s management team uses these non-GAAP financial measures to evaluate Merit’s profitability and efficiency, to compare operating results to prior periods, to evaluate changes in the operating results of its operating segments, and to measure and allocate financial resources internally. However, Merit’s management does not consider such non-GAAP measures in isolation or as an alternative to such measures determined in accordance with GAAP. Readers should consider non-GAAP measures used in this release in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP.  These non-GAAP financial measures exclude some, but not all, items that may affect Merit's net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such expenses in the calculation of non-GAAP earnings per share, non-GAAP gross margin and non-GAAP net income (in each case, as further illustrated in the reconciliation table below) because such amounts in any specific period may not directly correlate to the underlying performance of Merit’s business operations and can vary significantly between periods as a result of factors such as new acquisitions, non-cash expense related to amortization of previously acquired tangible and intangible assets, unusual compensation expenses or expense resulting from litigation or governmental proceedings.  Merit may incur similar types of expenses in the future, and the non-GAAP financial information included in this release should not be viewed as a statement or indication that these types of expenses will not recur.  Additionally, the non-GAAP financial measures used in this release may not be comparable with similarly titled measures of other companies.  Merit urges investors and potential investors to review the reconciliations of its non-GAAP financial measures to the comparable GAAP financial measures, and not to rely on any single financial measure to evaluate Merit’s business or results of operations. Constant Currency Reconciliation Merit’s revenue on a constant currency basis is prepared by translating the current-period reported sales of subsidiaries whose functional currency is other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period.  The constant currency revenue adjustment of $1.3 million for the three-month period ended March 31, 2017 was calculated using the applicable average foreign exchange rates for the three-month period ended March 31, 2016. Core Revenue Merit’s core revenue is defined as reported revenue excluding revenues from the acquisitions of the HeRO® Graft (excluded January 2017 only) and DFINE, Inc. in 2016 and Catheter Connections, Inc. and the critical care division of Argon Medical Devices, Inc. in 2017. Other Non-GAAP Financial Measure Reconciliation The following table sets forth supplemental financial data and corresponding reconciliations of non-GAAP net income and non-GAAP earnings per share to Merit’s net income and earnings per share prepared in accordance with GAAP for the three-month periods ended March 31, 2017 and 2016.  Non-GAAP gross margin is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets and inventory mark-up related to acquisitions. The non-GAAP income adjustments referenced in the following table do not reflect stock-based compensation expense of approximately $577,000 and $624,000 for the three-month periods ended March 31, 2017 and 2016, respectively. (a) Reflects the tax effect of the non-GAAP adjustments (d) Represents changes in the fair value of contingent consideration liabilities and contingent receivables as a result of acquisitions (e) Costs incurred in responding to an inquiry from the U.S. Department of Justice (f) Represents the bargain purchase gain realized from the acquisition of the critical care division of Argon Medical Devices, Inc. *Represents sales from the acquisitions of Hero in February 2016; DFINE in July 2016; Catheter Connections in 2017; and the critical care division of Argon Medical Devices in 2017 **The constant currency revenue adjustment of $1.3 million for the three-month period ended March 31, 2017 was calculated using the applicable average foreign exchange rates for the three-month period ended March 31, 2016. ABOUT MERIT Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 290 individuals.  Merit employs approximately 4,500 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; San Jose, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; and Singapore. FORWARD-LOOKING STATEMENTS Statements contained in this release which are not purely historical, including, without limitation, statements regarding Merit's forecasted plans, revenues, net income, financial results or anticipated or completed acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties such as those described in Merit's Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent filings with the Securities and Exchange Commission.  Such risks and uncertainties include risks relating to Merit's potential inability to successfully manage growth through acquisitions, including the inability to commercialize technology acquired through completed, proposed or future transactions; product recalls and product liability claims; expenditures relating to research, development, testing and regulatory approval or clearance of Merit's products and risks that such products may not be developed successfully or approved for commercial use; governmental scrutiny and regulation of the medical device industry, including governmental inquiries, investigations and proceedings involving Merit; reforms to the 510(k) process administered by the U.S. Food and Drug Administration; restrictions on Merit's liquidity or business operations resulting from its current debt agreements; infringement of Merit's technology or the assertion that Merit's technology infringes the rights of other parties; the potential of fines, penalties or other adverse consequences if Merit's employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; laws and regulations targeting fraud and abuse in the healthcare industry; potential for significant adverse changes in governing regulations; changes in tax laws and regulations in the United States or other countries; increases in the prices of commodity components; negative changes in economic and industry conditions in the United States or other countries; termination or interruption of relationships with Merit's suppliers, or failure of such suppliers to perform; fluctuations in exchange rates;  concentration of a substantial portion of Merit's revenues among a few products and procedures; development of new products and technology that could render Merit's existing products obsolete; market acceptance of new products; volatility in the market price of Merit's common stock; modification or limitation of governmental or private insurance reimbursement policies; changes in healthcare policies or markets related to healthcare reform initiatives; failure to comply with applicable environmental laws; changes in key personnel; work stoppage or transportation risks; introduction of products in a timely fashion; price and product competition; availability of labor and materials; fluctuations in and obsolescence of inventory; and other factors referred to in Merit's Annual Report on Form 10-K for the year ended December 31, 2016 and other materials filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates. TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Services, Inc., in the United States and other jurisdictions.


News Article | April 27, 2017
Site: globenewswire.com

DENVER, April 27, 2017 (GLOBE NEWSWIRE) -- Air Methods, the global leader in emergency air medical services and air tourism, today announced the appointment of two key executives: Cory Theriot and Alan Einisman. Theriot joins Air Methods as vice president of Safety and Risk Management, and Alan Einisman as vice president and chief compliance officer. Prior to joining Air Methods, Theriot served as vice president of Safety and Quality Assurance for Era Helicopters, where he developed global safety teams, led reduction of incident rates, developed advance compliance programs and served as a steering committee member of HeliOffshore. As the head of the safety and risk management department, he is responsible for the oversight and continued implementation of the safety management systems (SMS) program at Air Methods. In addition, he will guide, measure, analyze, and provide recognition for safety efforts across the Company. “Safety plays a very important role at Air Methods, and we’re excited to welcome Cory to the executive team,” said Aaron Todd, Air Methods’ chief executive officer. “He brings nearly two decades of global aviation experience with the exceptional ability to lead teams while enhancing safety performance and achieving quality gains.” Einisman most recently served as vice president of International Compliance and Senior Associate General Counsel for UnitedHealth Group, where he oversaw international-compliance matters and activities across the family of companies. During his 10-year career with UnitedHealth Group, Einisman also provided legal support to a UnitedHealthcare business unit and also managed UnitedHealth Group’s compliance and ethics program. In his new role, Einisman is responsible for overseeing and monitoring the development and implementation of Air Methods’ corporate compliance program. "Alan brings significant compliance and legal experience to the leadership team," said Crystal Gordon, Air Methods' executive vice president, general counsel and corporate secretary. "His expertise will support our movement forward, as he is committed to the further development of compliance and improving our processes for our team members." Air Methods Corporation (www.airmethods.com) is the global leader in air medical transportation. The Air Medical Services Division is the largest provider of air medical transport services in the United States. The United Rotorcraft Division specializes in the design and manufacture of aeromedical and aerospace technology. The Tourism Division is comprised of Sundance Helicopters, Inc. and Blue Hawaiian Helicopters, which provide helicopter tours and charter flights in the Las Vegas/Grand Canyon region and Hawaii, respectively. Air Methods’ fleet of owned, leased or maintained aircraft features over 450 helicopters and fixed wing aircraft.


TORONTO, ON--(Marketwired - May 05, 2017) - In an informative session on Tuesday, May 23, 2017 at 11:00am EST (4pm BST/UK), industry experts Nina Baluja, Senior Medical Director of Medical Services and Luke Gill, Executive Director of Oncology, Strategic Development, both from Premier Research, will discuss the promising approaches in immuno-oncology drug development including checkpoint inhibitors, antibody drug conjugates, autologous cellular immunotherapy, and oncolytic viruses. This webinar will explore each of these, along with challenges in researching these compounds and recommendations to improve your odds of success. Immuno-modulating agents such as interleukin-2 and interferon have been used to treat some solid malignancies for years, but their use has generally been limited to cancers considered immunogenic - for example, melanoma and kidney cancers. Today, multiple immuno-oncology pathways are in development. For instance, checkpoint inhibitors include monoclonal antibodies that target the cytotoxic T-lymphocyte associated antigen 4 (CTLA-4). Examples are ipilimumab - marketed as Yervoy - a drug that binds to the CTLA-4 on T cells and is indicated for treatment of unresectable metastatic melanoma, and programmed-death drugs such as pembrolizumab (Keytruda) that activate the immune system to attack tumors. Response and efficacy of oncology agents is measured by RECIST (Response Evaluation Criteria in Solid Tumors), a set of published rules that define when cancer patients improve, stay the same, or worsen. This webinar will discuss why these criteria do not easily apply in immuno-oncology and how these realities gave rise to the immune-related response criteria - published rules that define when tumors respond, stabilize, or worsen. Effective site training is essential when planning trials of immuno-oncology agents. In addition, combination studies should be planned early. This webinar will reveal how sufficient planning can reveal if a combination with a chemotherapy or other agent provides better efficacy without increasing toxicity. For details or to register for this complimentary event visit: http://xtalks.com/Expanding-Potential-of-Immuno-Oncology-Therapies.html Premier Research is a leading contract research organization serving the needs of biotechnology, pharmaceutical, and medical device companies worldwide. The company has a wealth of experience in the execution of global, regional, and local clinical development programs, with a special focus on addressing unmet needs in areas such as analgesia, CNS, rare diseases, medical device and diagnostics, oncology, and pediatric research. Premier Research operates in 84 countries and employs more than 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. With its mission to improve productivity in clinical development, the company aligns itself with the mission of its customers to bring new medical treatments to patients promptly, accurately, and cost-effectively. To learn more about Premier Research visit: premier-research.com Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit http://xtalks.com


News Article | May 2, 2017
Site: en.prnasia.com

BEIJING, May 2, 2017 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2016 with the U.S. Securities and Exchange Commission. An electronic copy of the annual report on Form 20-F can be accessed on Concord Medical's investor relations website at http://ir.concordmedical.com and on the SEC's website at www.sec.gov. Shareholders may receive a hard copy of Concord Medical's audited financial statements for the fiscal year ended December 31, 2016 free of charge upon request. Requests should be submitted to http://ir.concordmedical.com. Concord Medical Services Holdings Limited is a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China. As of December 31, 2016, the Company operated a network of 127 centers with 76 hospital partners that spanned 53 cities and 25 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, the Company provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. As part of its high-end cancer hospital development strategy and oversea business extension, the Company acquired Concord Cancer Hospital, a private hospital in Singapore in April, 2015. For more information, please see http://ir.concordmedical.com. For more information, please contact: Concord Medical Services  Mr. Ting Jia (Chinese and English) +86 10 5903 6688 (ext. 809) ting.jia@concordmedical.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/concord-medical-files-2016-annual-report-on-form-20-f-300449393.html


News Article | February 21, 2017
Site: globenewswire.com

* Constant currency revenue, core revenue, non-GAAP EPS, non-GAAP gross margin and non-GAAP net income (referenced on the following page) are non-GAAP financial measures. A reconciliation of these and other non-GAAP financial measures used in this release to their most directly comparable GAAP financial measure is included under the heading “Non-GAAP Financial Measures” below. SOUTH JORDAN, Utah, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy, today announced sales of $157.7 million for the quarter ended December 31, 2016, an increase of 14.0% over sales of $138.4 million for the quarter ended December 31, 2015.  On a constant currency basis, sales for the fourth quarter of 2016 would have been up 14.9% over sales for the comparable quarter of 2015. For the year ended December 31, 2016, Merit’s sales were $603.8 million, an increase of 11.4% over sales of $542.1 million, for the year ended December 31, 2015.  On a constant currency basis, sales for the year ended December 31, 2016 would have been up 12.3% over sales for 2015. Merit’s GAAP net income for the fourth quarter of 2016 was $7.5 million, or $0.17 per share, compared to $6.4 million, or $0.14 per share, for the fourth quarter of 2015, up primarily due to decreases in SG&A and R&D expenses as a percentage of sales, partially offset by increased interest expense due to higher debt balances, primarily as a result of Merit’s acquisition of DFINE, Inc. in July 2016. Merit’s non-GAAP net income* for the quarter ended December 31, 2016 was $13.8 million, or $0.31 per share, up 28.2% compared to $10.8 million, or $0.24 per share, for the quarter ended December 31, 2015. Merit’s GAAP net income for the year ended December 31, 2016 was $20.1 million, or $0.45 per share, compared to $23.8 million, or $0.53 per share, for the year ended December 31, 2015, down primarily as a result of restructuring costs related to the acquisition of DFINE, Inc. in July 2016.  Merit’s non-GAAP net income* for the year ended December 31, 2016 was $45.1 million, or $1.01 per share, up 17.1% compared to $38.5 million, or $0.87 per share, for 2015. Merit’s sales by category for the three and twelve months ended December 31, 2016, compared to the corresponding periods in 2015, were as follows: “We are pleased to complete year two of our three-year plan,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer.  “With the introduction of a number of new products in the beginning of 2017, we look forward to continued growth accompanied by continued expansion of gross margins and profits.” “We believe the recently announced acquisitions of an Argon Medical Devices business unit and Catheter Connections serve both tactical and strategic objectives,” Lampropoulos said.  “We believe the Argon transaction will enable us to participate in tenders which previously were not available due to vacancies in our product line, especially reusable transducers.  Additionally, we recently came to a preliminary agreement with our longstanding Japanese distributor to transfer licenses and customers to us.  Almost 50% of the Argon business we acquired is sold in Japan and other parts of Asia.  We intend to combine the acquired Argon business and the Merit-branded products into one business.  When completed, we believe the new combined business unit will substantially improve our growth prospects in Japan.” “We believe the Catheter Connections products complement the Argon products and provide a substantial value proposition to both domestic hospitals as well as international opportunities,” Lampropoulos continued.  “We expect that this product line, which has had substantial distribution gaps globally, will enhance company growth and profits as we integrate the injection molding and a portion of manufacturing.  We have already initiated new product development in both of the acquired businesses.” 2017 GUIDANCE Based upon information currently available to Merit's management, Merit estimates that for the year ending December 31, 2017, absent material acquisitions or non-recurring transactions, Merit's revenues will be in the range of $713-$723 million, an increase of approximately 18-20%, compared to revenues of $603.8 million for the year ended December 31, 2016.  Also, based on information currently available to Merit's management, Merit estimates that, absent material acquisitions or non-recurring transactions, Merit's GAAP earnings per share for 2017 will be in the range of $0.54-$0.60 and non-GAAP* earnings per share will be in the range of $1.15-$1.20. Merit’s financial guidance for the year ending December 31, 2017 is subject to risks and uncertainties, including, but not limited to, potential accounting adjustments attributable to Merit’s ongoing valuation of intangibles and other financial assets acquired from Argon Medical Devices, Inc. and Catheter Connections, Inc., as well as risks and uncertainties identified in Merit’s public filings. CONFERENCE CALL Merit will hold its investor conference call (conference ID 62632957) today, Tuesday, February 21, 2017, at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific).  The domestic telephone number is (844) 578-9672, and the international number is (508) 637-5656.  A live webcast will also be available for the conference call at merit.com. Although Merit’s financial statements are prepared in accordance with accounting principles which are generally accepted in the United States of America (“GAAP”), Merit’s management believes that certain non-GAAP financial measures referred to in this release provide investors with useful information regarding the underlying business trends and performance of Merit’s ongoing operations and can be useful for period-over-period comparisons of such operations.  Non-GAAP financial measures used in this release include: Merit’s management team uses these non-GAAP financial measures to evaluate Merit’s profitability and efficiency, to compare operating results to prior periods, to evaluate changes in the operating results of each segment, and to measure and allocate financial resources internally. However, Merit’s management does not consider such non-GAAP measures in isolation or as an alternative to such measures determined in accordance with GAAP. Readers should consider non-GAAP measures used in this release in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP.  These non-GAAP financial measures exclude some, but not all, items that may affect Merit's net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such expenses in the calculation of non-GAAP net income, non-GAAP gross margin and non-GAAP earnings per share (in each case, as further illustrated in the reconciliation table below) because such amounts in any specific period may not directly correlate to the underlying performance of Merit’s business operations and can vary significantly between periods as a result of factors such as new acquisitions, non-cash expense related to amortization of previously acquired tangible and intangible assets, unusual compensation expenses or expense resulting from litigation or governmental proceedings.  Merit may incur similar types of expenses in the future, and the non-GAAP financial information included in this release should not be viewed as a statement or indication that these types of expenses will not recur.  Additionally, the non-GAAP financial measures used in this release may not be comparable with similarly titled measures of other companies.  Merit urges investors and potential investors to review the reconciliations of its non-GAAP financial measures to the comparable GAAP financial measures, and not to rely on any single financial measure to evaluate Merit’s business or results of operations. Constant Currency Reconciliation Merit’s revenue on a constant currency basis is prepared by translating the current-period reported sales of subsidiaries whose functional currency is other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period.  The constant currency revenue adjustments of $1.3 million and $4.9 million for the three and twelve-month periods ended December 31, 2016, respectively, were calculated using the applicable average foreign exchange rates for the three and twelve-month periods ended December 31, 2015. Core Revenue Merit’s core revenue is defined as reported revenue excluding revenues from the acquisitions of the HeRO® Graft and DFINE, Inc. in 2016. Other Non-GAAP Financial Measure Reconciliation The following table sets forth supplemental financial data and corresponding reconciliations of non-GAAP net income and non-GAAP earnings per share to Merit’s net income and earnings per share prepared in accordance with GAAP, in each case, for the three and twelve-month periods ended December 31, 2016 and 2015.  Non-GAAP gross margin is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets, inventory mark-up and severance expense related to acquisitions.  The non-GAAP income adjustments referenced in the following table do not reflect stock-based compensation expense of approximately $593,000 and $600,000 for the three-month periods ended December 31, 2016 and 2015, respectively, and approximately $2.5 million and $2.2 million for the twelve-month periods ended December 31, 2016 and 2015, respectively. (a) Reflects the tax effect of the non-GAAP adjustments (b) Represents abandoned patents (c) Represents costs related to acquisitions (d) Represents changes in the fair value of contingent consideration liabilities and contingent receivables as a result of acquisitions (e) Costs associated with the termination of our agreement with a third-party contract manufacturer in Tijuana, Mexico (f) Costs incurred in responding to an inquiry from the U.S. Department of Justice Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 200 individuals.  Merit employs approximately 4,500 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; San Jose, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; and Singapore. FORWARD-LOOKING STATEMENTS Statements contained in this release which are not purely historical, including, without limitation, statements regarding Merit's forecasted plans, revenues, net income, financial results or anticipated or completed acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties such as those described in Merit's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Reports on Form 10-Q filed during 2016.  Such risks and uncertainties include risks relating to Merit's potential inability to successfully manage growth through acquisitions, including the inability to commercialize technology acquired through completed, proposed or future transactions; product recalls and product liability claims; expenditures relating to research, development, testing and regulatory approval or clearance of Merit's products and risks that such products may not be developed successfully or approved for commercial use; governmental scrutiny and regulation of the medical device industry, including governmental inquiries, investigations and proceedings involving Merit; reforms to the 510(k) process administered by the U.S. Food and Drug Administration; restrictions on Merit's liquidity or business operations resulting from its current debt agreements; infringement of Merit's technology or the assertion that Merit's technology infringes the rights of other parties; the potential of fines, penalties or other adverse consequences if Merit's employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; laws and regulations targeting fraud and abuse in the healthcare industry; potential for significant adverse changes in governing regulations; changes in tax laws and regulations in the United States or other countries; increases in the prices of commodity components; negative changes in economic and industry conditions in the United States or other countries; termination or interruption of relationships with Merit's suppliers, or failure of such suppliers to perform; fluctuations in exchange rates;  concentration of a substantial portion of Merit's revenues among a few products and procedures; development of new products and technology that could render Merit's existing products obsolete; market acceptance of new products; volatility in the market price of Merit's common stock; modification or limitation of governmental or private insurance reimbursement policies; changes in healthcare policies or markets related to healthcare reform initiatives; failure to comply with applicable environmental laws; changes in key personnel; work stoppage or transportation risks;  introduction of products in a timely fashion; price and product competition; availability of labor and materials; fluctuations in and obsolescence of inventory; and other factors referred to in Merit's Annual Report on Form 10-K for the year ended December 31, 2015 and other materials filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates. TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Services, Inc., in the United States and other jurisdictions.


News Article | March 2, 2017
Site: globenewswire.com

SANTA ROSA, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- The assets of Sierra Lifeflight, the air medical transport company located in Bishop, CA, have been purchased by REACH Medical Holdings, LLC, headquartered in Santa Rosa, CA. Under new ownership, the company will continue operating from their base at the Eastern Sierra Regional Airport. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/bc5cb901-69eb-4d1c-ab90-7f887a62456f For the past 24 years, Sierra Lifeflight was a family-owned air ambulance operation with a long history of excellent service transporting patients to needed care. In remote areas like Inyo and Mono counties, having an air ambulance service is critical. Hospitals often need their patients transferred to higher levels of care than can be provided locally, and the time it takes to go by ground ambulance is not an option for some patients. Sierra Lifeflight will continue providing air medical transports for the region. Medical transports are flown by a pilot with thousands of hours of flight experience on board a medically equipped airplane. The medical crew consists of highly skilled and licensed flight nurses and paramedics who administer critical care throughout the transport. “We started this business in 1993 right here in Bishop. We have built a company that has served this community for over twenty years. We want that legacy to continue. We looked at the people we wanted to run this business and we chose REACH because they are a well-respected company with 30 years in this industry. Their dedication to their patients, their experience in the air ambulance business, and their forward-thinking leadership made this the right decision for us. We are confident Sierra Lifeflight will continue to serve this community for many years to come,” stated James Marchio, CEO and owner of Sierra Lifeflight, on sharing the news of the company’s sale. Sierra Lifeflight joins REACH Air Medical Services, Cal-Ore Life Flight, and CALSTAR Air Medical Services owned by REACH Medical Holdings. Together, they form part of the largest air medical transport organization in the western United States. Sean Russell, president of REACH Medical Holdings, said he believes this will be good for the residents of Inyo and Mono counties. “Sierra Lifeflight will continue to serve the eastern Sierra region as an air medical resource with added support and benefits. With the largest network of fixed wing and rotor wing air ambulances in California, REACH will be able to further support Sierra Lifeflight to assure they are able to continue serving the eastern Sierra communities. Additionally, air ambulance membership will now be available through AirMedCare Network. For just $65 a year for your entire household, membership covers all out-of-pocket costs for a medically necessary flight--not only by Sierra Lifeflight, but also by REACH, CALSTAR, Cal-Ore Life Flight, or any of the Network’s more than 260 helicopter and airplane bases across 32 states.” Mike Patterson, previously Program Director at Sierra Lifeflight, will be continuing with the company as Regional Director of Program Operations. Mr. Patterson notes, “I am really happy Sierra Lifeflight will continue this service. This has been a valuable asset for this community and the patients we have transported. I want to let our customers and our patients know that we’re still here, and we’re going to take great care of them.” About REACH Medical Holdings, LLC REACH Medical Holdings, LLC owns REACH Air Medical Services, Cal-Ore Life Flight, CALSTAR and Sierra Lifeflight and operates hospital-branded air programs. The company provides air medical transports using helicopters and airplanes from more than 45 bases located in California, Oregon, Nevada, Montana, Wyoming, Colorado and Texas. The company has nearly 900 employees, most of whom are highly skilled nurses, paramedics, pilots and aircraft maintenance technicians. To date, the company has transported more than 135,000 patients to needed care. For more information, visit www.REACHair.com. About AirMedCare Network AirMedCare Network is America’s largest air ambulance membership network. The company offers membership covering out-of-pocket costs for an emergency air transport by any of their providers. Sierra Lifeflight, REACH Air Medical Services, Cal-Ore Life Flight, and CALSTAR are providers to the AirMedCare Network. The company has more than 2.6 million members served by more than 260 air ambulance bases across 32 states. For more information, visit www.AirMedCareNetwork.com.


News Article | February 21, 2017
Site: www.prweb.com

Women Veterans Interactive will host its Inaugural Jocks and Pearls Gala in Atlanta, Georgia on Friday, March 24, 2017. Professional athletes, celebrities and military members will gather for this noteworthy event to raise awareness and funds to support homeless women veterans and their children. The statistics surrounding women veterans are staggering to say the least. Out of 2.2 million woman veterans, 1 in 25 become homeless, 85% of women veterans that leave the military don't feel prepared for the civilian sector, women veterans are more likely to be unemployed than male veterans and women non-veterans, and they also suffer from high rates of Military Sexual Trauma and Post Traumatic Stress Disorder. “The word homeless and women veterans should never be in the same sentence and as a country we must collectively do more,” said Ginger Miller, White House Champion of Change for Women Veterans, Founder and CEO of Women Veterans Interactive. Miller knows the road of a homeless veteran all too well, as she was homeless in the early 90’s after receiving a medical discharge out of the U.S. Navy. The road wasn’t easy for Miller who was taking care of her husband, a disabled veteran who suffered from post-traumatic stress disorder, and their 2.5 year-old son, all while being homeless. In 2015, Centric TV featured Ginger’s story entitled, Get to know Women Veterans Interactive’s, Ginger Miller. Jocks and Pearls is more than a gala, it’s an initiative designed to use professional sports as a vehicle to raise awareness to support the brave women who have served and sacrificed for our country. The initiative kicks off with the Jocks and Pearls Gala-Atlanta, followed by Jocks and Pearls Gala–DC on November 11, 2017, Jocks and Pearls Celebrity Golf Tournaments and Jocks and Pearls PSA’s. This year’s inaugural event is hosted by actor, producer Torrei Hart, who is a woman veteran. “For years I didn’t consider myself to be a woman veteran because I was a Reservist, but that all changed when I met Ginger Miller, the CEO of Women Veterans Interactive. I am a proud woman veteran and want to do my part to make sure that my sister veterans have a place to lay their heads at night. I look forward to hosting this awesome event,” said Hart. Steven Nelson, Cornerback with Kansas City Chiefs will serve as the first NFL Jocks and Pearls Ambassador. “I was totally unaware that women veterans are becoming homeless at alarming rates and to be honest, every time I thought about a veteran, I would think of a man. I’m honored to be a part of the Jocks and Pearls initiative to help raise awareness and funds for homeless women veterans. To assist with raising funds, I am donating a signed autographed jersey for the Jocks and Pearls silent auction,” said Nelson. Sports Entrepreneur & Columnist, Mandy Antoniacci is on board with this awesome initiative. Mandy will deliver a Keynote that will address using the social and cultural impact of sport and its ability to incite change in humanity. “What are you doing to support homeless women veterans?” I was so taken aback when I heard this question. When you think of homeless veterans, you never think of women. As someone who resides in the industry of sport, health, and wellness - the specific disciplines that can help these women better transition into their lives post serving our nation, exercising my voice to help foster change was a no-brainer.”- Mandy Antoniacci Actress Angela Robinson of Tyler Perry's "The Haves and the Have Nots" will deliver the Keynote Address for the gala and Actor Peter Parros, also of Tyler Perry's "The Haves and the Have Nots", will make a special celebrity guest appearance. Parros is the son of a Marine Corps veteran. Other Jocks and Pearls Ambassadors include Army veterans Nathan Banks, Partner, McDowell Information Group LLC; Les Davis, Director of Military Affairs at International Education Corporation; Marcel Callahan, Medical Services Corps Officer; and Rick Clark, NASCAR Team Owner. We are grateful to all of our Ambassadors for assisting us with raising awareness and funds for homeless women veterans. Tickets are on sale now for this star-studded, notable event and can be purchased at Jocks and Pearls Atlanta About Women Veterans Interactive (WVI) Women Veterans Interactive is a national not-for-profit organization dedicated to serving and supporting women veterans and their families through Advocacy, Empowerment, Interaction, Outreach and Unification. Recognized as experts on Women Veterans issues, our aim is to eradicate homelessness; improve healthcare and education delivery; and develop a network where there is a free exchange of experiences and solutions that will empower and assist women veterans in living full productive lives. Since inception in 2011, Women Veterans Interactive has supported over 1500 women veterans and continues to meet women veterans at their points of need. For more information, visit WVI at Women Veterans Interactive.

Loading Medical Services collaborators
Loading Medical Services collaborators